Michael Lübbert

28.0k citations
296 papers · 12.7k · 2 hit papers · h-index 60

Impact in

  • Hematology top 0.05%
    • Acute Myeloid Leukemia Research
    • Hematopoietic Stem Cell Transplantation
    • Chronic Myeloid Leukemia Treatments
  • Genetics top 0.2%
    • Myeloproliferative Neoplasms: Diagnosis and Treatment

Papers in

    • Acute Myeloid Leukemia Research 214
    • Chronic Myeloid Leukemia Treatments 28
    • Hematopoietic Stem Cell Transplantation 25
    • Epigenetics and DNA Methylation 69
    • Histone Deacetylase Inhibitors Research 53
    • Retinoids in leukemia and cellular processes 29
    • Protein Degradation and Inhibitors 28

Michael Lübbert

285 papers receiving 12.5k citations

Michael Lübbert's Hit Papers

Low-Dose Decitabine Versus Best Supportive Care in Elderly Patients With Intermediate- or High-Risk Myelodysplastic Syndrome (MDS) Ineligible for Intensive Chemotherapy: Final Results of the Randomized Phase III Study of the European Organisation for Research and Treatment of Cancer Leukemia Group and the German MDS Study Group 2011 · 408 citations
4080+6+12Years since publication100200300400500

Peers

Michael Lübbert
Comparison fields: 5 of 140
  • Hematology 6.9k
  • Genetics 1.9k
  • Molecular Biology 6.7k
  • Oncology 1.8k
  • Cancer Research 941
Replace Paresh Vyas with:
Paresh Vyas United Kingdom
Kevin Shannon United States
Tomoki Naoe Japan
Francesco Lo‐Coco Italy
Stephen D. Nimer United States
Christine Chomienne France
Valeria Santini Italy
Bruno Quesnel France
Kenneth Kaushansky United States
Vincent H. J. van der Velden Netherlands
Michael Lübbert relative to Paresh Vyas United Kingdom Paresh Vyas's profile →
Citations per field
00.5×1.5×1.8×
Paresh Vyas · 1×
Citations per year

Countries citing papers authored by Michael Lübbert

Since Specialization
Citations

This map shows the geographic impact of Michael Lübbert's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Michael Lübbert with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Michael Lübbert more than expected).

Fields of papers citing papers by Michael Lübbert

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Michael Lübbert. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Michael Lübbert. The network helps show where Michael Lübbert may publish in the future.

Co-authors

The 25 scholars most cited alongside Michael Lübbert, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Michael Lübbert Line = papers co-authored together Michael Lübbert links everyone, so they are left out of the graph.

All Works

20 of 20 papers shown

Showing the 20 most-cited of 296 papers — load more, or switch the sort, to bring in the rest.

#Work
1
New insights into the prognostic impact of the karyotype in MDS and correlation with subtypes: evidence from a core dataset of 2124 patients
Hit paper breakdown →
2007540
2 2006493
3 2000453
4
Low-Dose Decitabine Versus Best Supportive Care in Elderly Patients With Intermediate- or High-Risk Myelodysplastic Syndrome (MDS) Ineligible for Intensive Chemotherapy: Final Results of the Randomized Phase III Study of the European Organisation for Research and Treatment of Cancer Leukemia Group and the German MDS Study Group
Hit paper breakdown →
2011408
5 2002400
6 2010323
7 2016291
8 2011277
9 2006259
10 2009246
11 2015191
12 2010189
13 2014187
14 2010183
15 2003176
16 2001174
17 2011172
18 2003170
19 2000164
20 1991155

About Michael Lübbert

Michael Lübbert is a scholar working on Hematology, Molecular Biology, Genetics, Public Health, Environmental and Occupational Health and Oncology, having authored 296 papers that have together received 12.7k indexed citations. Recurring topics across this work include Acute Myeloid Leukemia Research (214 papers), Epigenetics and DNA Methylation (69 papers), Histone Deacetylase Inhibitors Research (53 papers), Acute Lymphoblastic Leukemia research (39 papers), Retinoids in leukemia and cellular processes (29 papers), Chronic Myeloid Leukemia Treatments (28 papers), Protein Degradation and Inhibitors (28 papers) and Hematopoietic Stem Cell Transplantation (25 papers). The work is most often cited by research in Hematology (6.9k citations), Genetics (1.9k citations), Molecular Biology (6.7k citations), Oncology (1.8k citations) and Cancer Research (941 citations). Michael Lübbert has collaborated with scholars based in Germany, United States and Netherlands. Frequent co-authors include Barbara Deschler-Baier, Manfred Jung, Rainer Claus, Pierre W. Wijermans, Björn Hackanson, P. Wijermans, Arnold Ganser, Björn Rüter, F. Herrmann and André Bosly. Their work appears in journals such as Blood, Leukemia Research, Annals of Hematology, Leukemia and British Journal of Haematology.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact